Research programme: dual aurora/FLT kinase inhibitors - Sareum

Drug Profile

Research programme: dual aurora/FLT kinase inhibitors - Sareum

Latest Information Update: 29 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sareum
  • Class Small molecules
  • Mechanism of Action Aurora kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Vascular endothelial growth factor receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Cancer

Most Recent Events

  • 24 Feb 2016 Preclinical trials in Acute myeloid leukaemia in China
  • 24 Feb 2016 Sareum has patent protection for aurora/FLT3 kinase inhibitors in Europe and USA
  • 11 Feb 2011 Preclinical development is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top